ClinicalTrials.Veeva

Menu
H

Howard University | Department of Psychiatry and Behavioral Sciences (CBOT-OUD Group)

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Hydroxyurea
Aspirin
Buprenorphine
Emricasan
Estrogen
TAU
elbasvir
Cannabidiol
paritaprevir
Riociguat

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 55 total trials

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two d...

Enrolling
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

The ASPREE Cancer Endpoint Study (ACES), an ancillary study of the ASPirin in the Prevention of Events in the Elderly (ASPREE) Study, will allow for...

Active, not recruiting
Cancer
Drug: Aspirin
Drug: Placebo

The overarching goal of this study phase, Phase II component is to implement Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Manage...

Enrolling
Opioid Use Disorder
Substance Use Disorders
Combination Product: CBOT with olfactory stimulants & OFC tasks
Combination Product: EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)

A multisite effectiveness-implementation study will be conducted in three sites to evaluate interventions to improve engagement and retention in MOUD...

Begins enrollment in 1 month
Opioid Use Disorder
Behavioral: BT-MOUD with Buprenorphine
Behavioral: HC-MOUD Only

To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.

Active, not recruiting
Vitiligo
Device: RECELL® Autologous Cell Harvesting Device

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination o...

Enrolling
Sickle Cell Disease
Drug: HU - Hydroxyurea
Drug: Placebo

Trial sponsors

University of Southern California logo
Howard University logo
A
E
National Institutes of Health (NIH) logo
Grifols logo
H
Mass General Brigham logo
Yale University logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems